In future clinical treatment of SMA, gene therapy strategies need to be developed for application in the treatment of patients with SMA-III and SMA-IV, as well as for an accurate safety assessment and prognostic analysis of existing clinical treatment strategies. Here, SMN1 is linked to proximal spinal muscular atrophy.